very nice summary
CDC Issues Updated Recommendations for VariZIG — Physician’s First Watch
CDC Issues Updated Recommendations for VariZIG
By Amy Orciari Herman
The CDC has issued updated recommendations for the use of VariZIG, the varicella-zoster immunoglobulin given for postexposure prophylaxis in high-risk patients and for whom the varicella vaccine is contraindicated.
As reported in MMWR, the CDC has extended the treatment window for VariZIG to 10 days (instead of 4) after exposure to varicella zoster — although the earlier, the better. In addition, the period of eligibility for use in premature infants has been extended to include exposures that occur throughout the length of hospitalization for prematurity.
VariZIG is recommended for the following groups: immunocompromised patients without apparent immunity; newborns whose mothers have signs of varicella in the peripartum period; hospitalized premature infants born at 28 weeks or later whose mothers don't have evidence of immunity, or those born before 28 weeks, regardless of their mothers' immunity status; and pregnant women without immunity.
VariZIG is available from one U.S. distributor, FFF Enterprises.